|1.||Trainer, P J: 22 articles (04/2012 - 04/2000)|
|2.||van der Lely, A J: 15 articles (11/2015 - 04/2000)|
|3.||Drake, W M: 15 articles (04/2012 - 04/2000)|
|4.||Parkinson, C: 12 articles (11/2006 - 04/2000)|
|5.||Bidlingmaier, M: 11 articles (08/2013 - 04/2000)|
|6.||Strasburger, C J: 10 articles (11/2009 - 04/2000)|
|7.||Trainer, Peter J: 10 articles (10/2009 - 01/2002)|
|8.||Besser, G M: 9 articles (08/2005 - 04/2000)|
|9.||Strasburger, Christian J: 8 articles (07/2014 - 10/2003)|
|10.||Buchfelder, Michael: 8 articles (07/2014 - 01/2007)|
01/01/2007 - "The GH receptor antagonist pegvisomant is a highly effective new treatment option in acromegaly. "
07/01/2001 - "Pegvisomant is a GH receptor antagonist and highly efficacious new treatment for acromegaly. "
01/01/2007 - "The GPOS database provides important information about treatment modalities, safety and efficacy of pegvisomant in patients with acromegaly."
07/01/2001 - "This is further evidence of the efficacy of pegvisomant in the management of acromegaly and has important implications for determining optimum glucocorticoid replacement."
01/13/2001 - "In a short term study (3 months) pegvisomant was shown to be an effective treatment for acromegaly. "
04/05/2014 - "Additionally, we will describe experiments in which the GHA was discovered, review results of pegvisomant's preclinical and clinical trials, and provide data suggesting pegvisomant's therapeutic value in selected types of cancer. "
02/01/2011 - "The objective of the study was to investigate the clinical, immunohistological, and molecular factors conditioning tumor growth in patients taking pegvisomant. "
02/01/2011 - "Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study."
07/01/2009 - "Therefore, neuroradiological monitoring of tumor extension and volume was performed in the German Pegvisomant Observational Study, which covers 87% of patients treated with pegvisomant in Germany. "
11/01/2008 - "We present details on 9 of 304 patients in clinical trials with pegvisomant who experienced tumor growth within the first year of treatment. "
|3.||Pituitary Neoplasms (Pituitary Adenoma)
03/01/2015 - "The reported low incidence of pituitary tumor size increase and liver enzyme elevations are reassuring and support the positive benefit-risk of pegvisomant therapy."
10/01/2005 - "Treatment of pituitary tumors: pegvisomant."
05/01/2005 - "Recently GH receptor blockers (pegvisomant) were introduced in the treatment of GH-producing pituitary adenomas. "
01/01/2003 - "Two patients had an increase in pituitary tumor volume during pegvisomant therapy; however, the relationship to pegvisomant therapy was not clear. "
07/01/2009 - "Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study."
03/01/2002 - "Successful management using pegvisomant increases lowered baseline serum TC and LDL levels, restoring the distribution of values to that of the general population, and improves insulin resistance. "
12/01/2002 - "The results show that the Pegvisomant is an effective agent for improving insulin resistance in subjects who have acromegaly and that this effect is independent of weight loss. "
01/01/2007 - "The addition of pegvisomant treatment was accompanied by a significant improvement in insulin and glycemic responses to the oral glucose tolerance test, without any significant changes in fasting plasma glucose, glycosylated haemoglobin, homeostatic model assessment-derived insulin resistance index and homeostatic model assessment-derived beta-cell function. "
02/01/2001 - "We conclude that although these results were obtained from an acute study, and long-term administration of pegvisomant could render different results, blockade of the GHR in the nonfasting state induces tissue-specific changes in insulin sensitivity, resulting in an increase in glucose and insulin levels (indicating insulin resistance of liver/muscle), but probably also in an increase in lipogenesis (indicating normal insulin sensitivity of adipose tissue). "
08/01/2013 - "Only 2 cases with potentially resectable adenomas from the German Pegvisomant Observational Study (GPOS) had been operated. "
02/01/2010 - "Because previous studies suffer from inhomogenous magnetic resonance imaging (MRI) protocols, this prospective study examined the long-term course of adenoma volume during pegvisomant therapy by standardized MRI. "
08/01/2013 - "Pituitary surgery might be indicated on pegvisomant treatment, due to side effects, adenoma growth or intention to cure after primary treatment. "
08/01/2005 - "Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant."
01/01/2010 - "Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy."
|1.||Insulin-Like Growth Factor I (IGF-1)
|2.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|6.||Somatotropin Receptors (Growth Hormone Receptor)
|8.||Dopamine Agonists (Dopamine Agonist)
|10.||Growth Hormone (Somatotropin)
|2.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)